ImmunityBio Inc. Common Stock vs SK Hynix — how do they compare? ImmunityBio Inc. Common Stock trades at $10.7 (market cap $10.51B), while SK Hynix trades at $170.56 (market cap $891.31B). The key difference: SK Hynix is far larger — about 84.8× ImmunityBio Inc. Common Stock's market cap, and SK Hynix pays a 0.06% dividend while ImmunityBio Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold ImmunityBio Inc. Common Stock for 0 Days and SK Hynix for 10 Days on average.
| IBRX | SKHY | |
|---|---|---|
Market Cap | $10.51B | $891.31B |
Volume | 10,445,785 | 22,268,296 |
Sector | Health | Technology |
52-Week High | $11.55 | $198.63 |
52-Week Low | $1.98 | $126.79 |
Typical Hold Time | 0 Days | 10 Days |
Enterprise Value | $10.97B | $841.45B |
Dividend Yield | — | 0.06% |
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
ImmunityBio develops immune-based therapies for cancer and infectious diseases. Its programs are designed to activate and strengthen the body’s immune response.
Read more on IBRX →SK hynix is a South Korean semiconductor company that manufactures memory products, including DRAM and NAND flash. Its high-bandwidth memory (HBM) products are designed for high-performance computing and AI applications.
Read more on SKHY →